CCK8-R5

(0)No Reviews yet
$50.00
SKU: CCK8-R5-p

In Stock

Available: 50

DSHB Data Sheet

Catalog Fields

Clone ID/Product Name: CCK8-R5
Available to For-Profits: Yes
Alternate Antibody Name:
Gene Symbol: Cck
Ab Isotype: Rabbit IgG
Gene Name:
Antibody Registry ID: AB_2753319 
Uniprot ID: P01355 
RRID:  
Entrez Gene ID: 25298 
Clonality: Polyclonal
Immunogen: Recombinant sulfated CCK8-BSA
Clone:
Immunogen Sequence:
Myeloma Strain:
Epitope Mapped: No
Antigen Name: Cholescystokinin C-terminal octapeptide CCK8
Epitope Location or Sequence:
Alternate Antigen Name:
Deposit Date: 10/2/2018
Antigen Molecular Weight: 12.8 kDa
Depositor: Beinfeld, M.C.
Antigen Sequence:
Depositor Institution: Tufts University
Antigen Species: Rat
Depositor Notes: This polyclonal antisera cross-reacts with gastrin and CCK33.
Host Species: rabbit
Hybridoma Cells Available (Non-Profit): No
Confirmed Species Reactivity: Canine, Frog, Guinea Pig, Human, Monkey, Mouse, Pig, Rat, Sheep, Turtle
Additional Information: This polyclonal is used for RIA applications.
Predicted Species Reactivity:  
Human Protein Atlas:  
Additional Characterization:  
Recommended Applications: ELISA, Immunofluorescence, Immunohistochemistry
All cell products contain the antimicrobial ProClin. Click here for additional information.
These hybridomas were created by your colleagues. Please acknowledge the hybridoma contributor and the Developmental Studies Hybridoma Bank (DSHB) in the Materials and Methods of your publications. Please email the citation to us.
For your Materials & Methods section:
CCK8-R5 was deposited to the DSHB by Beinfeld, M.C. (DSHB Hybridoma Product CCK8-R5)
Storage and Handling Recommendations
Although many cell products are maintained at 4°C for years without loss of activity, shelf-life at 4°C is highly variable. For immediate use, short term storage at 4°C up to two weeks is recommended. For long term storage, divide the solution into volumes of no less than 20 ul for freezing at -20°C or -80°C. The small volume aliquot should provide sufficient reagent for short term use. Freeze-thaw cycles should be avoided. For concentrate or bioreactor products, an equal volume of glycerol, a cryoprotectant, may be added prior to freezing.
Usage Recommendations
The optimal Ig concentration for an application varies by species and antibody affinity. For each product, the antibody titer must be optimized for every application by the end user laboratory. A good starting concentration for immunohistochemistry (IHC), immunofluorescence (IF), and immunocytochemistry (ICC) when using mouse Ig is 2-5 ug/ml. For western blots, the recommended concentration range of mouse Ig 0.2-0.5 ug/ml. In general, rabbit antibodies demonstrate greater affinity and are used at a magnitude lower Ig concentration for initial testing. The recommended concentrations for rabbit Ig are 0.2-0.5 ug/ml (IF, IHC and ICC) and 20-50 ng/ml (WB).

84 References

  • Initial Publication
  • IF References
  • IHC References
  • ELISA References
  • All References
  • Initial Publication
    IF References
    IHC References

    Origin of the cholecystokinin-containing fibers in the rat caudatoputamen.
    Brownstein MJ
    Science (New York, N.Y.) 215.4529 (1982 Jan 8): 187-8.

    CCK-containing terminals in the hippocampus are derived from intrinsic neurons: an immunohistochemical and radioimmunological study.
    Oertel WH
    Brain research 224.1 (1981 Nov 9): 180-4.

    Cholecystokinin-immunoreactive neurons in rat and monkey cerebral cortex make symmetric synapses and have intimate associations with blood vessels.
    Beinfeld MC
    Proceedings of the National Academy of Sciences of the United States of America 80.8 (1983 Apr): 2400-4.

    Effects of time and experience on hippocampal neurochemistry after damage to the CA3 subfield.
    Cummins CJ
    Pharmacology, biochemistry, and behavior 18.4 (1983 Apr): 551-61.

    Cholecystokinin in the hypothalamo-hypophyseal system.
    Brownstein MJ
    Brain research 299.1 (1984 May 7): 186-9.

    Brainstem projection to the hypothalamic ventromedial nucleus in the rat: a CCK-containing long ascending pathway.
    Heimer L
    Brain research 303.2 (1984 Jun 15): 225-31.

    Cholecystokinin and cultured spinal neurons. Immunohistochemistry, receptor binding, and neurophysiology.
    Skirboll LR
    Annals of the New York Academy of Sciences 448. (1985): 403-12.

    Cholecystokinin and cultured spinal neurons. Immunohistochemistry, receptor binding, and neurophysiology.
    Skirboll LR
    Annals of the New York Academy of Sciences 448. (1985): 403-12.

    The distribution of cholecystokinin-8 in the central nervous system of turtles: an immunohistochemical and biochemical study.
    Beinfeld MC
    Brain research bulletin 15.2 (1985 Aug): 167-81.

    The co-occurrence of a substance P-like peptide and cholecystokinin-8 in a fiber system of turtle cortex.
    Krause JE
    The Journal of neuroscience : the official journal of the Society for Neuroscience 5.6 (1985 Jun): 1527-44.

    Cholecystokinin (CCK) gene-related peptides: distribution and characterization of immunoreactive pro-CCK and an amino-terminal pro-CCK fragment in rat brain.
    Beinfeld MC
    Brain research 344.2 (1985 Oct 7): 351-5.

    The subcellular distribution of peptides immunoreactive for the amino-terminal of pro-cholecystokinin in rat brain.
    Beinfeld MC
    Regulatory peptides 12.1 (1985 Sep): 59-66.

    The subcellular distribution of peptides immunoreactive for the carboxyl-terminal extension of cholecystokinin in rat brain.
    Beinfeld MC
    Neuropeptides 6.3 (1985 Jun): 239-45.

    Exogenous cholecystokinin (CCK) reduces neonatal rat brain opioid receptor density and CCK levels.
    Coscia CJ
    Brain research 429.1 (1987 Mar): 139-46.

    Peptides in rat brain immunoreactive for the amino terminus of cholecystokinin 33: distribution and chromatography.
    Beinfeld MC
    Biochemical and biophysical research communications 149.3 (1987 Dec 31): 902-7.

    Cholecystokinin concentrations and peptide immunoreactivity in the intact and deafferented medullary dorsal horn of the rat.
    Zahm DS
    The Journal of comparative neurology 326.1 (1992 Dec 1): 22-43.

    Inhibition of pro-cholecystokinin (CCK) sulfation by treatment with sodium chlorate alters its processing and decreases cellular content and secretion of CCK 8.
    Beinfeld MC
    Neuropeptides 26.3 (1994 Mar): 195-200.

    ELISA References

    The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay.
    Brownstein MJ
    Brain research 212.1 (1981 May 11): 51-7.

    Prohormone convertase 7 is necessary for the normal processing of cholecystokinin in mouse brain.
    Beinfeld MC
    Biochemical and biophysical research communications 482.4 (2017 Jan 22): 1190-1193.

    Postnatal ontogeny of cholecystokinin receptors in rat brain.
    Paul SM
    Brain research 213.1 (1981 May 25): 237-41.

    CCK-containing terminals in the hippocampus are derived from intrinsic neurons: an immunohistochemical and radioimmunological study.
    Oertel WH
    Brain research 224.1 (1981 Nov 9): 180-4.

    Actions of natural gastric inhibitory peptide on pancreatic acinar cells: due to contamination with cholecystokinin.
    Gardner JD
    Gastroenterology 82.1 (1982 Jan): 20-5.

    Origin of the cholecystokinin-containing fibers in the rat caudatoputamen.
    Brownstein MJ
    Science (New York, N.Y.) 215.4529 (1982 Jan 8): 187-8.

    Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei.
    Palkovits M
    Brain research 238.1 (1982 Apr 22): 260-5.

    Corpus callosum lesions increase cholecystokinin concentrations in cortical areas with homeotopic connections.
    Brownstein MJ
    Brain research 240.1 (1982 May 20): 151-3.

    HPLC and RIA of cholecystokinin peptides in the vertebrate neural retina.
    Beinfeld MC
    Brain research 246.2 (1982 Aug 26): 315-8.

    Cerebral ventricular transport and uptake: importance for CCK-mediated satiety.
    Beinfeld MC
    Peptides 3.6 (1982 Nov-Dec): 963-8.

    Effects of time and experience on hippocampal neurochemistry after damage to the CA3 subfield.
    Cummins CJ
    Pharmacology, biochemistry, and behavior 18.4 (1983 Apr): 551-61.

    Extra-hippocampal projections of CCK neurons of the hippocampus and subiculum.
    Brenneman DE
    Peptides 4.3 (1983 May-Jun): 331-4.

    Cholecystokinin peptides in the brain and pituitary of the bullfrog Rana catesbeiana: distribution and characterization.
    Brownstein MJ
    Brain research 268.1 (1983 May 23): 192-6.

    The distribution of cholecystokinin and vasoactive intestinal peptide in rhesus monkey brain as determined by radioimmunoassay.
    Pert CB
    Neuropeptides 3.5 (1983 Jul): 337-44.

    The development of motilin, cholecystokinin and vasoactive intestinal peptide immunoreactivity in the forebrain and hindbrain of the rat, as determined by radioimmunoassay.
    O'Dorisio TM
    Brain research 312.1 (1983 Oct): 146-50.

    Cholecystokinin in the hypothalamo-hypophyseal system.
    Brownstein MJ
    Brain research 299.1 (1984 May 7): 186-9.

    Brainstem projection to the hypothalamic ventromedial nucleus in the rat: a CCK-containing long ascending pathway.
    Heimer L
    Brain research 303.2 (1984 Jun 15): 225-31.

    The development of motilin-like immunoreactivity in the rat cerebellum and pituitary as determined by radioimmunoassay.
    Beinfeld MC
    Neuroscience letters 48.3 (1984 Aug 10): 267-72.

    Failure of chronic haloperidol treatment to alter levels of cholecystokinin in the rat brain striatum and olfactory tuberclenucleus accumbens area.
    Beinfeld MC
    Neuropeptides 4.5 (1984 Sep): 421-3.

    Cholecystokinin and cultured spinal neurons. Immunohistochemistry, receptor binding, and neurophysiology.
    Skirboll LR
    Annals of the New York Academy of Sciences 448. (1985): 403-12.

    Cholecystokinin and cultured spinal neurons. Immunohistochemistry, receptor binding, and neurophysiology.
    Skirboll LR
    Annals of the New York Academy of Sciences 448. (1985): 403-12.

    Cholecystokinin innervation of the ventral striatum: a morphological and radioimmunological study.
    Palkovits M
    Neuroscience 14.2 (1985 Feb): 427-53.

    The subcellular distribution of peptides immunoreactive for the carboxyl-terminal extension of cholecystokinin in rat brain.
    Beinfeld MC
    Neuropeptides 6.3 (1985 Jun): 239-45.

    The distribution of cholecystokinin-8 in the central nervous system of turtles: an immunohistochemical and biochemical study.
    Beinfeld MC
    Brain research bulletin 15.2 (1985 Aug): 167-81.

    The subcellular distribution of peptides immunoreactive for the amino-terminal of pro-cholecystokinin in rat brain.
    Beinfeld MC
    Regulatory peptides 12.1 (1985 Sep): 59-66.

    The distribution of chromatographic characterization of an amino-terminal fragment of cholecystokinin (CCK) 58 in rat brain.
    Beinfeld MC
    Biochemical and biophysical research communications 127.3 (1985 Mar 29): 720-5.

    The co-occurrence of a substance P-like peptide and cholecystokinin-8 in a fiber system of turtle cortex.
    Krause JE
    The Journal of neuroscience : the official journal of the Society for Neuroscience 5.6 (1985 Jun): 1527-44.

    Cholecystokinin (CCK) gene-related peptides: distribution and characterization of immunoreactive pro-CCK and an amino-terminal pro-CCK fragment in rat brain.
    Beinfeld MC
    Brain research 344.2 (1985 Oct 7): 351-5.

    Peptides in rat brain immunoreactive for the carboxyl terminal extension of cholecystokinin: distribution and chromatography.
    Beinfeld MC
    Peptides 6.5 (1985 Sep-Oct): 857-60.

    Cholecystokinin (CCK) gene-related peptides: distribution and characterization of immunoreactive pro-CCK and an amino-terminal pro-CCK fragment in rat brain.
    Beinfeld MC
    Brain research 344.2 (1985 Oct 7): 351-5.

    Increase in hypothalamic cholecystokinin following acute and chronic morphine.
    Olney JW
    Brain research 367.1-2 (1986 Mar 5): 405-7.

    Vasoactive intestinal polypeptide (VIP) inhibits potassium-induced release of cholecystokinin (CCK) from rat caudato-putamen but not from cerebral cortex.
    Beinfeld MC
    Neuropeptides 8.3 (1986 Oct): 287-93.

    Modulation of cholecystokinin release from posterior nucleus accumbens by D-2 dopamine receptor.
    Wang RY
    Brain research 397.2 (1986 Nov 12): 253-8.

    Exogenous cholecystokinin (CCK) reduces neonatal rat brain opioid receptor density and CCK levels.
    Coscia CJ
    Brain research 429.1 (1987 Mar): 139-46.

    The regulation of cholecystokinin release from rat caudatoputamen in vitro.
    Beinfeld MC
    Brain research 407.1 (1987 Mar 24): 110-6.

    Hypothalamic neurotoxins alter the content of immunoreactive cholecystokinin in pituitary.
    Olney JW
    Brain research 407.2 (1987 Mar 31): 390-3.

    Lithium preincubation stimulates the potassium-induced release of cholecystokinin from slices of cerebral cortex and caudate-putamen incubated in vitro.
    Beinfeld MC
    Brain research 413.2 (1987 Jun 16): 365-7.

    Phorbol esters stimulate the potassium-induced release of cholecystokinin from slices of cerebral cortex, caudato-putamen and hippocampus incubated in vitro.
    Beinfeld MC
    Biochemical and biophysical research communications 153.1 (1988 May 31): 372-6.

    Role of glucagon in cholecystokinin-stimulated bile flow in dogs.
    Beinfeld MC
    The American journal of physiology 254.6 Pt 1 (1988 Jun): G864-9.

    Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat.
    Fibiger HC
    Brain research 480.1-2 (1989 Feb 20): 178-83.

    Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice.
    Johnson FE
    American journal of surgery 157.4 (1989 Apr): 386-94.

    Establishment of a cholecystokinin-producing rat medullary thyroid carcinoma cell line.
    Dixon JE
    Endocrinology 125.2 (1989 Aug): 850-6.

    Cholecystokinin, dopamine and schizophrenia.
    Yao JK
    Psychopharmacology bulletin 26.3 (1990): 377-80.

    Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compounds.
    Beinfeld MC
    Brain research 522.2 (1990 Jul 9): 224-6.

    Neuropeptide content and connectivity of the rat claustrum.
    Palkovits M
    Brain research 523.2 (1990 Jul 23): 245-50.

    Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response.
    Garver DL
    Progress in neuro-psychopharmacology & biological psychiatry 15.5 (1991): 601-9.

    Cholecystokinin release from the rat caudate-putamen, cortex and hippocampus is increased by activation of the D1 dopamine receptor.
    Beinfeld MC
    The Journal of pharmacology and experimental therapeutics 260.1 (1992 Jan): 343-8.

    Regulation of cholecystokinin secretion from a rat medullary thyroid carcinoma cell line: role of calcium, cyclic nucleotides, glucocorticoids, neurotensin, and calcitonin gene-related peptide.
    Dixon JE
    Peptides 13.3 (1992 May-Jun): 545-50.

    CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects.
    Beinfeld MC
    The American journal of psychiatry 149.5 (1992 May): 691-3.

    CCK mRNA expression, pro-CCK processing, and regulated secretion of immunoreactive CCK peptides by rat insulinoma (RIN 5F) and mouse pituitary tumor (AtT-20) cells in culture.
    Beinfeld MC
    Neuropeptides 22.4 (1992 Aug): 213-7.

    Calcium-dependent pro-cholecystokinin V-9-M immunoreactive peptide release from rat brain slices and CCK-secreting rat medullary thyroid carcinoma cells in culture.
    Beinfeld MC
    Peptides 13.6 (1992 Nov-Dec): 1087-90.

    Cholecystokinin concentrations and peptide immunoreactivity in the intact and deafferented medullary dorsal horn of the rat.
    Zahm DS
    The Journal of comparative neurology 326.1 (1992 Dec 1): 22-43.

    CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects.
    Ballenger JC
    The American journal of psychiatry 150.7 (1993 Jul): 1099-101.

    Processing, release and metabolism of cholecystokinin in SK-N-MCIXC cells.
    Davis TP
    Neuropeptides 25.1 (1993 Jul): 19-30.

    Inhibition of pro-cholecystokinin (CCK) sulfation by treatment with sodium chlorate alters its processing and decreases cellular content and secretion of CCK 8.
    Beinfeld MC
    Neuropeptides 26.3 (1994 Mar): 195-200.

    Expression of antisense PC1 in stably transfected RIN5F cells significantly reduces CCK 8 biosynthesis.
    Beinfeld MC
    Regulatory peptides 59.2 (1995 Oct 20): 221-7.

    Specificity and kinetic studies on the cleavage of various prohormone mono- and paired-basic residue sites by yeast aspartic protease 3.
    Loh YP
    The Journal of biological chemistry 271.8 (1996 Feb 23): 4168-76.

    Cholecystokinin (CCK) release from rat brain slices in vitro is enhanced by agents which elevate intracellular cAMP.
    Beinfeld MC
    Regulatory peptides 67.2 (1996 Dec 3): 75-7.

    Cleavage of CCK 33 by recombinant PC2 in vitro.
    Beinfeld MC
    Biochemical and biophysical research communications 231.1 (1997 Feb 3): 149-52.

    Prohormone convertase 1 is necessary for the formation of cholecystokinin 8 in Rin5F and STC-1 cells.
    Beinfeld MC
    The Journal of biological chemistry 272.14 (1997 Apr 4): 9450-6.

    Prohormone convertase 2 is necessary for the formation of cholecystokinin-22, but not cholecystokinin-8, in RIN5F and STC-1 cells.
    Beinfeld MC
    Endocrinology 138.9 (1997 Sep): 3620-3.

    Cholecystokinin (CCK) levels are greatly reduced in the brains but not the duodenums of Cpe(fat)/Cpe(fat) mice: a regional difference in the involvement of carboxypeptidase E (Cpe) in pro-CCK processing.
    Beinfeld MC
    Endocrinology 138.9 (1997 Sep): 4034-7.

    Prohormone convertase 1 (PC1) when expressed with pro cholecystokinin (pro CCK) in L cells performs three endoproteolytic cleavages which are observed in rat brain and in CCK-expressing endocrine cells in culture, including the production of glycine and arginine extended CCK8.
    Beinfeld MC
    Biochemical and biophysical research communications 248.3 (1998 Jul 30): 538-41.

    Identification of glycine-extended CCK peptides in endocrine cells and modulation of CCK amide and CCK Gly content and secretion from endocrine tumor cells by an inhibitor of amidation.
    Venkatakrishnan K
    Peptides 19.8 (1998): 1393-8.

    Adult carboxypeptidase E-deficient fat/fat mice have a near-total depletion of brain CCK 8 accompanied by a massive accumulation of glycine and arginine extended CCK: identification of CCK 8 Gly as the immediate precursor of CCK 8 in rodent brain.
    Beinfeld MC
    Endocrine 9.3 (1998 Dec): 329-32.

    Lovastatin is a potent inhibitor of cholecystokinin secretion in endocrine tumor cells in culture.
    Beinfeld MC
    Peptides 21.4 (2000 Apr): 553-7.

    Adult carboxypeptidase E-deficient fat/fat mice have a near-total depletion of brain CCK 8 accompanied by a massive accumulation of glycine and arginine extended CCK: identification of CCK 8 Gly as the immediate precursor of CCK 8 in rodent brain.
    Beinfeld MC
    Endocrine 9.3 (1998 Dec): 329-32.

    PC2 and 7B2 null mice demonstrate that PC2 is essential for normal pro-CCK processing.
    Beinfeld MC
    Biochemical and biophysical research communications 273.1 (2000 Jun 24): 188-91.

    Role of tyrosine sulfation and serine phosphorylation in the processing of procholecystokinin to amidated cholecystokinin and its secretion in transfected AtT-20 cells.
    Beinfeld MC
    Biochemistry 39.45 (2000 Nov 14): 13825-30.

    Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids.
    Connolly K
    Neuroscience letters 301.1 (2001 Mar 23): 69-71.

    Neuronal cell lines expressing PC5, but not PC1 or PC2, process Pro-CCK into glycine-extended CCK 12 and 22.
    Beinfeld MC
    Peptides 22.8 (2001 Aug): 1271-7.

    OLETF (Otsuka Long-Evans Tokushima Fatty) rats that lack the CCK 1 (A) receptor develop less behavioral sensitization to repeated cocaine treatment than wild type LETO (Long Evans Tokushima Otsuka) rats.
    Pierce RC
    Peptides 22.8 (2001 Aug): 1285-90.

    Biosynthesis and post-translational processing of site-directed endoproteolytic cleavage mutants of Pro-CCK in AtT-20 cells.
    Beinfeld MC
    Biochemistry 41.2 (2002 Jan 15): 570-8.

    CCK processing by pituitary GH3 cells, human teratocarcinoma cells NT2 and hNT differentiated human neuronal cells evidence for a differentiation-induced change in enzyme expression and pro CCK processing.
    Wang W
    Life sciences 70.11 (2002 Feb 1): 1251-8.

    Cocaine treatment increases extracellular cholecystokinin (CCK) in the nucleus accumbens shell of awake, freely moving rats, an effect that is enhanced in rats that are behaviorally sensitized to cocaine.
    Pierce RC
    Journal of neurochemistry 81.5 (2002 Jun): 1021-7.

    Production, purification, and characterization of rat pro-CCK from serum-free adapted Drosophila cells.
    Beinfeld MC
    Protein expression and purification 31.1 (2003 Sep): 56-63.

    Cleavage-site mutagenesis alters post-translation processing of Pro-CCK in AtT-20 cells.
    Beinfeld MC
    Biochemistry 43.29 (2004 Jul 27): 9502-11.

    Regional brain cholecystokinin changes as a function of friendly and aggressive social interactions in rats.
    Moskal JR
    Brain research 1025.1-2 (2004 Oct 29): 75-84.

    Regional brain cholecystokinin changes as a function of rough-and-tumble play behavior in adolescent rats.
    Moskal JR
    Peptides 27.1 (2006 Jan): 172-7.

    Cholecystokinin levels in prohormone convertase 2 knock-out mouse brain regions reveal a complex phenotype of region-specific alterations.
    Marchand JE
    The Journal of biological chemistry 280.46 (2005 Nov 18): 38410-5.

    Inhibition of PC5 expression decreases CCK secretion and increases PC2 expression.
    Beinfeld MC
    Peptides 27.4 (2006 Apr): 901-4.

    Inhibition of prohormone convertase 1 (PC1) expression in cholecystokinin (CCK) expressing At-T20 cells decreased cellular content and secretion of CCK and caused a shift in molecular forms of CCK secreted.
    Marchand JE
    Peptides 27.4 (2006 Apr): 905-10.

    Brain regional neuropeptide changes resulting from social defeat.
    Moskal JR
    Behavioral neuroscience 121.6 (2007 Dec): 1364-71.

    Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival.
    Attie AD
    Endocrinology 151.8 (2010 Aug): 3577-88.

    Prohormone convertase 7 is necessary for the normal processing of cholecystokinin in mouse brain.
    Beinfeld MC
    Biochemical and biophysical research communications 482.4 (2017 Jan 22): 1190-1193.

    Cathepsin L plays a major role in cholecystokinin production in mouse brain cortex and in pituitary AtT-20 cells: protease gene knockout and inhibitor studies.
    Hook V
    Peptides 30.10 (2009 Oct): 1882-91.

    All References

    Origin of the cholecystokinin-containing fibers in the rat caudatoputamen.
    Brownstein MJ
    Science (New York, N.Y.) 215.4529 (1982 Jan 8): 187-8.

    CCK-containing terminals in the hippocampus are derived from intrinsic neurons: an immunohistochemical and radioimmunological study.
    Oertel WH
    Brain research 224.1 (1981 Nov 9): 180-4.

    Cholecystokinin-immunoreactive neurons in rat and monkey cerebral cortex make symmetric synapses and have intimate associations with blood vessels.
    Beinfeld MC
    Proceedings of the National Academy of Sciences of the United States of America 80.8 (1983 Apr): 2400-4.

    Effects of time and experience on hippocampal neurochemistry after damage to the CA3 subfield.
    Cummins CJ
    Pharmacology, biochemistry, and behavior 18.4 (1983 Apr): 551-61.

    Cholecystokinin in the hypothalamo-hypophyseal system.
    Brownstein MJ
    Brain research 299.1 (1984 May 7): 186-9.

    Brainstem projection to the hypothalamic ventromedial nucleus in the rat: a CCK-containing long ascending pathway.
    Heimer L
    Brain research 303.2 (1984 Jun 15): 225-31.

    Cholecystokinin and cultured spinal neurons. Immunohistochemistry, receptor binding, and neurophysiology.
    Skirboll LR
    Annals of the New York Academy of Sciences 448. (1985): 403-12.

    The distribution of cholecystokinin-8 in the central nervous system of turtles: an immunohistochemical and biochemical study.
    Beinfeld MC
    Brain research bulletin 15.2 (1985 Aug): 167-81.

    The co-occurrence of a substance P-like peptide and cholecystokinin-8 in a fiber system of turtle cortex.
    Krause JE
    The Journal of neuroscience : the official journal of the Society for Neuroscience 5.6 (1985 Jun): 1527-44.

    Cholecystokinin (CCK) gene-related peptides: distribution and characterization of immunoreactive pro-CCK and an amino-terminal pro-CCK fragment in rat brain.
    Beinfeld MC
    Brain research 344.2 (1985 Oct 7): 351-5.

    The subcellular distribution of peptides immunoreactive for the amino-terminal of pro-cholecystokinin in rat brain.
    Beinfeld MC
    Regulatory peptides 12.1 (1985 Sep): 59-66.

    The subcellular distribution of peptides immunoreactive for the carboxyl-terminal extension of cholecystokinin in rat brain.
    Beinfeld MC
    Neuropeptides 6.3 (1985 Jun): 239-45.

    Exogenous cholecystokinin (CCK) reduces neonatal rat brain opioid receptor density and CCK levels.
    Coscia CJ
    Brain research 429.1 (1987 Mar): 139-46.

    Peptides in rat brain immunoreactive for the amino terminus of cholecystokinin 33: distribution and chromatography.
    Beinfeld MC
    Biochemical and biophysical research communications 149.3 (1987 Dec 31): 902-7.

    Cholecystokinin concentrations and peptide immunoreactivity in the intact and deafferented medullary dorsal horn of the rat.
    Zahm DS
    The Journal of comparative neurology 326.1 (1992 Dec 1): 22-43.

    Inhibition of pro-cholecystokinin (CCK) sulfation by treatment with sodium chlorate alters its processing and decreases cellular content and secretion of CCK 8.
    Beinfeld MC
    Neuropeptides 26.3 (1994 Mar): 195-200.

    Cholecystokinin innervation of the ventral striatum: a morphological and radioimmunological study.
    Palkovits M
    Neuroscience 14.2 (1985 Feb): 427-53.

    The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay.
    Brownstein MJ
    Brain research 212.1 (1981 May 11): 51-7.

    Prohormone convertase 7 is necessary for the normal processing of cholecystokinin in mouse brain.
    Beinfeld MC
    Biochemical and biophysical research communications 482.4 (2017 Jan 22): 1190-1193.

    Postnatal ontogeny of cholecystokinin receptors in rat brain.
    Paul SM
    Brain research 213.1 (1981 May 25): 237-41.

    Actions of natural gastric inhibitory peptide on pancreatic acinar cells: due to contamination with cholecystokinin.
    Gardner JD
    Gastroenterology 82.1 (1982 Jan): 20-5.

    Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei.
    Palkovits M
    Brain research 238.1 (1982 Apr 22): 260-5.

    Corpus callosum lesions increase cholecystokinin concentrations in cortical areas with homeotopic connections.
    Brownstein MJ
    Brain research 240.1 (1982 May 20): 151-3.

    HPLC and RIA of cholecystokinin peptides in the vertebrate neural retina.
    Beinfeld MC
    Brain research 246.2 (1982 Aug 26): 315-8.

    Cerebral ventricular transport and uptake: importance for CCK-mediated satiety.
    Beinfeld MC
    Peptides 3.6 (1982 Nov-Dec): 963-8.

    Extra-hippocampal projections of CCK neurons of the hippocampus and subiculum.
    Brenneman DE
    Peptides 4.3 (1983 May-Jun): 331-4.

    Cholecystokinin peptides in the brain and pituitary of the bullfrog Rana catesbeiana: distribution and characterization.
    Brownstein MJ
    Brain research 268.1 (1983 May 23): 192-6.

    The distribution of cholecystokinin and vasoactive intestinal peptide in rhesus monkey brain as determined by radioimmunoassay.
    Pert CB
    Neuropeptides 3.5 (1983 Jul): 337-44.

    The development of motilin, cholecystokinin and vasoactive intestinal peptide immunoreactivity in the forebrain and hindbrain of the rat, as determined by radioimmunoassay.
    O'Dorisio TM
    Brain research 312.1 (1983 Oct): 146-50.

    The development of motilin-like immunoreactivity in the rat cerebellum and pituitary as determined by radioimmunoassay.
    Beinfeld MC
    Neuroscience letters 48.3 (1984 Aug 10): 267-72.

    Failure of chronic haloperidol treatment to alter levels of cholecystokinin in the rat brain striatum and olfactory tuberclenucleus accumbens area.
    Beinfeld MC
    Neuropeptides 4.5 (1984 Sep): 421-3.

    The distribution of chromatographic characterization of an amino-terminal fragment of cholecystokinin (CCK) 58 in rat brain.
    Beinfeld MC
    Biochemical and biophysical research communications 127.3 (1985 Mar 29): 720-5.

    Peptides in rat brain immunoreactive for the carboxyl terminal extension of cholecystokinin: distribution and chromatography.
    Beinfeld MC
    Peptides 6.5 (1985 Sep-Oct): 857-60.

    Increase in hypothalamic cholecystokinin following acute and chronic morphine.
    Olney JW
    Brain research 367.1-2 (1986 Mar 5): 405-7.

    Vasoactive intestinal polypeptide (VIP) inhibits potassium-induced release of cholecystokinin (CCK) from rat caudato-putamen but not from cerebral cortex.
    Beinfeld MC
    Neuropeptides 8.3 (1986 Oct): 287-93.

    Modulation of cholecystokinin release from posterior nucleus accumbens by D-2 dopamine receptor.
    Wang RY
    Brain research 397.2 (1986 Nov 12): 253-8.

    The regulation of cholecystokinin release from rat caudatoputamen in vitro.
    Beinfeld MC
    Brain research 407.1 (1987 Mar 24): 110-6.

    Hypothalamic neurotoxins alter the content of immunoreactive cholecystokinin in pituitary.
    Olney JW
    Brain research 407.2 (1987 Mar 31): 390-3.

    Lithium preincubation stimulates the potassium-induced release of cholecystokinin from slices of cerebral cortex and caudate-putamen incubated in vitro.
    Beinfeld MC
    Brain research 413.2 (1987 Jun 16): 365-7.

    Phorbol esters stimulate the potassium-induced release of cholecystokinin from slices of cerebral cortex, caudato-putamen and hippocampus incubated in vitro.
    Beinfeld MC
    Biochemical and biophysical research communications 153.1 (1988 May 31): 372-6.

    Role of glucagon in cholecystokinin-stimulated bile flow in dogs.
    Beinfeld MC
    The American journal of physiology 254.6 Pt 1 (1988 Jun): G864-9.

    Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat.
    Fibiger HC
    Brain research 480.1-2 (1989 Feb 20): 178-83.

    Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice.
    Johnson FE
    American journal of surgery 157.4 (1989 Apr): 386-94.

    Establishment of a cholecystokinin-producing rat medullary thyroid carcinoma cell line.
    Dixon JE
    Endocrinology 125.2 (1989 Aug): 850-6.

    Cholecystokinin, dopamine and schizophrenia.
    Yao JK
    Psychopharmacology bulletin 26.3 (1990): 377-80.

    Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compounds.
    Beinfeld MC
    Brain research 522.2 (1990 Jul 9): 224-6.

    Neuropeptide content and connectivity of the rat claustrum.
    Palkovits M
    Brain research 523.2 (1990 Jul 23): 245-50.

    Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response.
    Garver DL
    Progress in neuro-psychopharmacology & biological psychiatry 15.5 (1991): 601-9.

    Cholecystokinin release from the rat caudate-putamen, cortex and hippocampus is increased by activation of the D1 dopamine receptor.
    Beinfeld MC
    The Journal of pharmacology and experimental therapeutics 260.1 (1992 Jan): 343-8.

    Regulation of cholecystokinin secretion from a rat medullary thyroid carcinoma cell line: role of calcium, cyclic nucleotides, glucocorticoids, neurotensin, and calcitonin gene-related peptide.
    Dixon JE
    Peptides 13.3 (1992 May-Jun): 545-50.

    CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects.
    Beinfeld MC
    The American journal of psychiatry 149.5 (1992 May): 691-3.

    CCK mRNA expression, pro-CCK processing, and regulated secretion of immunoreactive CCK peptides by rat insulinoma (RIN 5F) and mouse pituitary tumor (AtT-20) cells in culture.
    Beinfeld MC
    Neuropeptides 22.4 (1992 Aug): 213-7.

    Calcium-dependent pro-cholecystokinin V-9-M immunoreactive peptide release from rat brain slices and CCK-secreting rat medullary thyroid carcinoma cells in culture.
    Beinfeld MC
    Peptides 13.6 (1992 Nov-Dec): 1087-90.

    CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects.
    Ballenger JC
    The American journal of psychiatry 150.7 (1993 Jul): 1099-101.

    Processing, release and metabolism of cholecystokinin in SK-N-MCIXC cells.
    Davis TP
    Neuropeptides 25.1 (1993 Jul): 19-30.

    Expression of antisense PC1 in stably transfected RIN5F cells significantly reduces CCK 8 biosynthesis.
    Beinfeld MC
    Regulatory peptides 59.2 (1995 Oct 20): 221-7.

    Specificity and kinetic studies on the cleavage of various prohormone mono- and paired-basic residue sites by yeast aspartic protease 3.
    Loh YP
    The Journal of biological chemistry 271.8 (1996 Feb 23): 4168-76.

    Cholecystokinin (CCK) release from rat brain slices in vitro is enhanced by agents which elevate intracellular cAMP.
    Beinfeld MC
    Regulatory peptides 67.2 (1996 Dec 3): 75-7.

    Cleavage of CCK 33 by recombinant PC2 in vitro.
    Beinfeld MC
    Biochemical and biophysical research communications 231.1 (1997 Feb 3): 149-52.

    Prohormone convertase 1 is necessary for the formation of cholecystokinin 8 in Rin5F and STC-1 cells.
    Beinfeld MC
    The Journal of biological chemistry 272.14 (1997 Apr 4): 9450-6.

    Prohormone convertase 2 is necessary for the formation of cholecystokinin-22, but not cholecystokinin-8, in RIN5F and STC-1 cells.
    Beinfeld MC
    Endocrinology 138.9 (1997 Sep): 3620-3.

    Cholecystokinin (CCK) levels are greatly reduced in the brains but not the duodenums of Cpe(fat)/Cpe(fat) mice: a regional difference in the involvement of carboxypeptidase E (Cpe) in pro-CCK processing.
    Beinfeld MC
    Endocrinology 138.9 (1997 Sep): 4034-7.

    Prohormone convertase 1 (PC1) when expressed with pro cholecystokinin (pro CCK) in L cells performs three endoproteolytic cleavages which are observed in rat brain and in CCK-expressing endocrine cells in culture, including the production of glycine and arginine extended CCK8.
    Beinfeld MC
    Biochemical and biophysical research communications 248.3 (1998 Jul 30): 538-41.

    Identification of glycine-extended CCK peptides in endocrine cells and modulation of CCK amide and CCK Gly content and secretion from endocrine tumor cells by an inhibitor of amidation.
    Venkatakrishnan K
    Peptides 19.8 (1998): 1393-8.

    Adult carboxypeptidase E-deficient fat/fat mice have a near-total depletion of brain CCK 8 accompanied by a massive accumulation of glycine and arginine extended CCK: identification of CCK 8 Gly as the immediate precursor of CCK 8 in rodent brain.
    Beinfeld MC
    Endocrine 9.3 (1998 Dec): 329-32.

    Lovastatin is a potent inhibitor of cholecystokinin secretion in endocrine tumor cells in culture.
    Beinfeld MC
    Peptides 21.4 (2000 Apr): 553-7.

    PC2 and 7B2 null mice demonstrate that PC2 is essential for normal pro-CCK processing.
    Beinfeld MC
    Biochemical and biophysical research communications 273.1 (2000 Jun 24): 188-91.

    Role of tyrosine sulfation and serine phosphorylation in the processing of procholecystokinin to amidated cholecystokinin and its secretion in transfected AtT-20 cells.
    Beinfeld MC
    Biochemistry 39.45 (2000 Nov 14): 13825-30.

    Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids.
    Connolly K
    Neuroscience letters 301.1 (2001 Mar 23): 69-71.

    Neuronal cell lines expressing PC5, but not PC1 or PC2, process Pro-CCK into glycine-extended CCK 12 and 22.
    Beinfeld MC
    Peptides 22.8 (2001 Aug): 1271-7.

    OLETF (Otsuka Long-Evans Tokushima Fatty) rats that lack the CCK 1 (A) receptor develop less behavioral sensitization to repeated cocaine treatment than wild type LETO (Long Evans Tokushima Otsuka) rats.
    Pierce RC
    Peptides 22.8 (2001 Aug): 1285-90.

    Biosynthesis and post-translational processing of site-directed endoproteolytic cleavage mutants of Pro-CCK in AtT-20 cells.
    Beinfeld MC
    Biochemistry 41.2 (2002 Jan 15): 570-8.

    CCK processing by pituitary GH3 cells, human teratocarcinoma cells NT2 and hNT differentiated human neuronal cells evidence for a differentiation-induced change in enzyme expression and pro CCK processing.
    Wang W
    Life sciences 70.11 (2002 Feb 1): 1251-8.

    Cocaine treatment increases extracellular cholecystokinin (CCK) in the nucleus accumbens shell of awake, freely moving rats, an effect that is enhanced in rats that are behaviorally sensitized to cocaine.
    Pierce RC
    Journal of neurochemistry 81.5 (2002 Jun): 1021-7.

    Production, purification, and characterization of rat pro-CCK from serum-free adapted Drosophila cells.
    Beinfeld MC
    Protein expression and purification 31.1 (2003 Sep): 56-63.

    Cleavage-site mutagenesis alters post-translation processing of Pro-CCK in AtT-20 cells.
    Beinfeld MC
    Biochemistry 43.29 (2004 Jul 27): 9502-11.

    Regional brain cholecystokinin changes as a function of friendly and aggressive social interactions in rats.
    Moskal JR
    Brain research 1025.1-2 (2004 Oct 29): 75-84.

    Regional brain cholecystokinin changes as a function of rough-and-tumble play behavior in adolescent rats.
    Moskal JR
    Peptides 27.1 (2006 Jan): 172-7.

    Cholecystokinin levels in prohormone convertase 2 knock-out mouse brain regions reveal a complex phenotype of region-specific alterations.
    Marchand JE
    The Journal of biological chemistry 280.46 (2005 Nov 18): 38410-5.

    Inhibition of PC5 expression decreases CCK secretion and increases PC2 expression.
    Beinfeld MC
    Peptides 27.4 (2006 Apr): 901-4.

    Inhibition of prohormone convertase 1 (PC1) expression in cholecystokinin (CCK) expressing At-T20 cells decreased cellular content and secretion of CCK and caused a shift in molecular forms of CCK secreted.
    Marchand JE
    Peptides 27.4 (2006 Apr): 905-10.

    Brain regional neuropeptide changes resulting from social defeat.
    Moskal JR
    Behavioral neuroscience 121.6 (2007 Dec): 1364-71.

    Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival.
    Attie AD
    Endocrinology 151.8 (2010 Aug): 3577-88.

    Cathepsin L plays a major role in cholecystokinin production in mouse brain cortex and in pituitary AtT-20 cells: protease gene knockout and inhibitor studies.
    Hook V
    Peptides 30.10 (2009 Oct): 1882-91.

    Ratings & Reviews

    No reviews available

    Be the first to Write a Review